Business Wire

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced results from the ENZAMET trial presented at the 2026 ASCO Annual ...
Hosted on MSN

Genomic test helps flag early aggressive prostate cancer in African American patients

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...
News Medical

Decipher genomic analysis platform predicts tumor responsiveness to neoadjuvant chemotherapy in MIBC patients

GenomeDx Biosciences today announced that the robust Decipher® genomic analysis platform, successfully classified various subtypes of bladder cancer based on the genomic expression of certain ...
Business Wire

Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium

More than 15 abstracts showcase how the Veracyte Diagnostics Platform is advancing urologic cancer care with decisions guided by Decipher Prostate and Bladder tests SOUTH SAN FRANCISCO, ...
AOL

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced results from the ENZAMET trial presented at the 2026 ASCO Annual Meeting. The analysis demonstrates that the ...